Progression of Choroidal Neovascularization Following Injection of Pegaptanib Sodium (Macugen) in Two Eyes With Neovascular Age-related Macular Degeneration - 18/08/11
Inquiries to Sharon Fekrat, MD, FACS, Duke University Eye Center, Box 3802, Durham, NC 27710Résumé |
Purpose |
To describe two cases of neovascular age-related macular degeneration (AMD) that progressed despite a single intravitreal injection of pegaptanib sodium (Macugen) six weeks earlier.
Design |
Interventional case report.
Methods |
A 62-year-old man and a 76-year-old woman with occult and minimally classic lesions, respectively, each received a single injection of intravitreal pegaptanib.
Results |
Within six weeks of an intravitreal pegaptanib injection, the choroidal neovascularization (CNV) progressed. In one eye, the chronic occult lesion developed subfoveal classic CNV. In the other eye, the classic component of the minimally classic lesion tripled in size.
Conclusions |
A single dose of intravitreal pegaptanib was not effective in these two patients at six weeks. This report reminds the ophthalmologist to consider obtaining a fluorescein angiogram during follow-up after an intravitreal pegaptanib injection to monitor CNV lesion characteristics, particularly if the visual acuity decreases.
Le texte complet de cet article est disponible en PDF.Plan
Vol 142 - N° 4
P. 683 - octobre 2006 Retour au numéro
Article précédent
- Choroidal Ischemia After Photodynamic Therapy With Verteporfin for Choroidal Neovascularization
- Vincenzo Isola, Alfredo Pece, Maurizio Battaglia Parodi
- Intravitreal Injection of Bevacizumab (Avastin) as Adjunctive Treatment of Proliferative Diabetic Retinopathy
- John O. Mason, Peter A. Nixon, Milton F. White
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?